Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about HALO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Recombinant Human Hyaluronidase (rHuPH20) | Dehydration | Phase 4 · NCT01120431 | Withdrawn |
| large protein molecule | Rheumatoid Arthritis | Phase 4 · NCT00369187 | Completed |
| Nab-paclitaxel | Pancreatic Ductal Carcinoma | Phase 3 · NCT02715804 | Terminated |
| Pegvorhyaluronidase Alfa (PEGPH20) | Metastatic Pancreatic Adenocarcinoma | Phase 1/2 · NCT01959139 | Completed |
| Linagliptin | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… | Phase 1/2 · NCT03281369 | Terminated |
| Mitomycin | Bladder Cancer | Phase 1/2 · NCT00318643 | Completed |
| Fluorouracil | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… | Phase 1/2 · NCT03281369 | Terminated |
| PEGylated recombinant human hyaluronidase… | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… | Phase 1/2 · NCT03281369 | Terminated |
| Tiragolumab | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… | Phase 1/2 · NCT03281369 | Terminated |
| Irinotecan | Metastatic Pancreatic Adenocarcinoma | Phase 1/2 · NCT01959139 | Completed |
| Human C1-Esterase Inhibitor | Hereditary Angioedema | Phase 2 · NCT01426763 | Completed |
| Enoxaparin | Metastatic Pancreatic Cancer | Phase 2 · NCT01839487 | Completed |
| Motixafortide (BL-8040) | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… | Phase 1/2 · NCT03281369 | Terminated |
| Ceftriaxone | Healthy | Phase 1 · NCT00493220 | Completed |
| Cytokine-Inducible SH2-Containing Protein | Cholangiocarcinoma Non-resectable | Phase 1 · NCT03267940 | Terminated |
| Cohort 2: bococizumab 300 mg | Healthy | Phase 1 · NCT02667223 | Terminated |
Also used in these trials (approved or third-party drugs, not HALO's own candidates): Hyaluronidase, Insulin Aspart, Insulin Glulisine, Insulin Lispro, Relatlimab, Gemcitabine Hydrochloride, Leucovorin, Oxaliplatin, Paclitaxel, Pembrolizumab, Ramucirumab, Insulin Human.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
HALO holds $1.1B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HALO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vanguard Capital Management | Institution (13G, 5%+) | 6,173,547 | 5.41% | 2026-03-31 |
| Helen Torley PRESIDENT AND CEO, Director · +256,642 options |
Insider | 767,780 | 0.67% | 2026-11-12 |
| Matthew L. Posard Director · +6,040 options |
Insider | 53,609 | 0.05% | 2026-10-01 |
| Mark Howard Snyder SVP, CHIEF LEGAL OFFICER · +10,068 options |
Insider | 49,929 | 0.04% | 2026-06-12 |
| Bernadette Connaughton Director · +6,040 options |
Insider | 40,418 | 0.04% | 2026-08-10 |
| Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER · +52,352 options |
Insider | 38,494 | 0.03% | 2026-02-20 |
| Jeffrey William Henderson Director · +6,040 options |
Insider | 36,572 | 0.03% | 2026-05-05 |
| Barbara Gayle Duncan Director · +6,040 options |
Insider | 23,715 | 0.02% | 2026-05-05 |
| Mahesh Krishnan Director · +7,540 options |
Insider | 14,462 | 0.01% | 2026-06-29 |
| Cortney Caudill SVP, CHIEF OPERATING OFFICER · +75,676 options |
Insider | 7,055 | 0.01% | 2026-03-09 |
| James Paul Lang Director · +6,040 options |
Insider | 4,685 | 0.00% | 2026-05-05 |
| David A Ramsay EVP, PRESIDENT, DRUG DELIVERY · +56,055 options |
Insider | 4,592 | 0.00% | 2026-06-30 |
Share count 114,010,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HALO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →